The study will target the CD19 antigen-specific chimeric antigen receptor for (B-NHL) non-Hodgkin’s lymphoma. A retroviral vector MSKCC (“RetroNectin”) will be used for delivery, and results will be studied on 6 – 18 patients for 3 years.

Takara Bio news release, March 13, 2014